AAS C.V



CURRICULUM VITAE

Dr Abdul (Abdurrrazag) Shlebak

MBChB (Hons) MD FRCP FRCPath DIML

Consultant & Honorary Senior Lecturer in Haematology

[pic]

Address:

|Department of Haematology |Department of Haematology |

|Imperial College Healthcare NHS Trust |2nd floor, Catherine Lewis Centre |

|St Mary’s Hospital Campus |Hammersmith Hospital |

|Praed St |Du Cane Rd |

|London |London |

|W2 1NY |W12 0NN |

Contact details:

020 3312 6806, 02033133329 (work)

07795028882 (mobile)

02033122390 (fax)

Academic e-mail a.shlebak@imperial.ac.uk

NHS e-mail abdul.shlebak1@

Education:

MBChB (Hons) 1986

Faculty of Medicine, Tripoli University 1980-1986

Prizes and distinctions:

-Best Graduate Prize 1986

-Distinctions in pathology, histology,

biochemistry, anatomy, pharmacology 1981-1983

-Distinctions in ophthalmology, 1983-1984

community medicine, Obstetrics & Gynaecology

-Distinctions in Paediatrics and Medicine

1984-1986

Postgraduate Qualifications:

MRCP UK 1991

MRCPath 1995

FRCP Edin 2000

MD London University 2001

FRCP Lond 2003

FRCPath 2005

Diploma in Management and Leadership (CMI accredited)

Jointly sponsored by London School of Economics &

Imperial College, London 2011

GMC ((3634109)

Full GMC registration 1992

Haematology specialist register 1996

Consultant Haematologist/Honorary Senior Lecturer

Imperial College Healthcare, London (Charing Cross Hospital, Hammersmith Hospital & St Mary’s Hospital).

Duties include 14/09/1998-till date

Main duties:

-Consultant Haematologist/Honorary Senior Lecturer

-Haematology Unit Training Lead (UTL) for Haematology (29 trainees)

-Chairman of Haematology Local Faculty Group (LFG)

-Joint lead North West London (NWL) Pathology-Haematology & Blood Transfusion for (NWL includes, Imperial College Healthcare NHS Hospitals (Charing Cross Hospital, Hammersmith Hospital & St Mary’s Hospital), Chelsea & Westminster Hospital, Hillingdon Hospital & West Middlesex Hospital)

Pathology

• Joint lead for diagnostic haematology and blood Transfusion for NWLP.

• Deputy for the NWLP clinical director on the Medical Director Governance meeting

• The day-to-day running of haemostasis laboratory at St Mary’s Hospital Campus.

Clinical

• Share the attending and out-of-hours duties for haemostasis and thrombosis services at Imperial College Healthcare with 4 other colleagues 1 in 5.

• The day to day running of haemostasis laboratory, anticoagulant services, thrombophilia, and obstetric haematology clinics at St Mary’s Hospital campus.

• Share the inpatient care of patients with acquired and inherited coagulopathies and VTE.

• Actively participating in the advisory and Consulting “Genera Referral Services” for Imperial College Healthcare Haematology.

• Active participation of the electronic GP advisory services for Imperial College Healthcare Haematology.

• Lead in VTE task force for Imperial College Healthcare with active participation in production of NICE compliant local guidelines and CQUIN.

Academic

• Lead for training in the department of haematology at Imperial with 15 specialist registrars and 5 clinical fellows & 9 SHOs.

• Undergraduate and postgraduate student teaching

• Co-convenor and lecturer on the BSc haemostasis and thrombosis course.

• Support research of the causes of the recurrent miscarriage and its relation to thrombophilia and antiphospholipid syndrome.

• Regular contributor to teaching of trainees of other disciplines in Emergency medicine, GPs, ITU etc.

Professional and Management

• Examiner for Haemostasis and Thrombosis and exam setting for Part 2 examinations of the Royal College of Pathologists (UK).

• Member of Imperial Healthcare Thrombosis Committee

Clinical Excellence Award Bronze (2010)

Major contributions & achievement:

Local

• Revolutionise of anticoagulant services and establishment of outreach and community clinics

• Introduction of outpatient diagnosis & management of deep vein thrombosis- to incorporate the introduction of NOACs.

• Establishment of NICE-compliant thromboprophylaxis protocols for medical, surgical, oncolological and obstetrics in association with Imperial Thrombosis Committee

• The successful relocation of integrated haematopathology diagnostics including flow, cytogentics, molecular and morphology

• Restructuring of laboratory staffing 2008-2009

• On-going harmonisation and unification of haematology diagnostic technology and reference ranges across imperial sites

• Establishment of diagnostic immunophenotyping services for leukaemia and Lymphoma

National

• The national haematology lead for National Laboratory Medicine Catalogue.

• Royal College of Pathologist senior examiner and haemostasis & thrombosis committee panellist

International

• Examined for the Libyan Medical board

• Examiner for the Libyan Medical School Final MBChB

• Examiner for the College of Physician & Surgeons Pakistan

• Speaker for several international conferences

Recent Key Management Roles

September 2016-till date

Joint interim lead for Haematology & Blood Transfusion

May 2015-till date

Lead for blood sciences at Imperial College (Haematology and chemical pathology). The

2008-2012

Lead for Haematological pathology for Imperial College Healthcare Trust (including Hammersmith, Charing Cross, Chelsea & St Mary’s)

2006-2008

Lead for Laboratory Haematology at St Mary’s Hospital

2005-2010

Chair of the Thrombosis Committee, St Mary’s Hospital

2005-2008

Lead for pathology clinical governance, St Mary’s Hospital

2003-2007

Hospital Transfusion Team Chair

1998-2007

Deputy Chair Hospital Transfusion Committee

Developing local guidelines

VTE prevention in bariatric surgery.

Led on CQUIN-VTE prevention

Ambulatory care pathway for managing patients with VTE.

DIC: diagnosis & management

Regional analgesia in obstetrics

VTE prevention in surgery & gynecology

Heparin induced thrombocytopenia

Initiation of oral anticoagulation

Perioperative management of anticoagulation

Discharging patients on anticoagulation.

Anticoagulation: Self-monitoring

Imperial Haematology lead for VTE on thrombosis committee

Major haemorrhage protocol

Major obstetric haemorrhage protocol

Reversal of anticoagulation

Haematology post held:

Lecturer and senior clinical fellow (Senior Registrar) in Haematology 07/1996-09/1998

Royal Postgraduate Medical School/Imperial College School of Medicine, Department of Haematology, Hammersmith Hospital, London

Locum Consultant Haematologist 07/1997-07/1997

Chelsea and Westminster Hospital

Visiting haematology Senior Training scheme 07/1994-07/1996

Department of Haematology, Glasgow Royal Infirmary University NHS Trust Hospitals

Haematology Registrar rotation (Mersey Region) 08/1992-07/1994

Royal Liverpool University NHS Hospital and Clatterbridge Hospital

Haematology Registrar (fixed term) 09/1991-08/1992

Department of Haematology, Glasgow Royal Infirmary University NHS Trust Hospitals

Publications

Peer reviewed

1. Salem A. Beshyah, Issam M. Hajjaji2, Wanis H. Ibrahim, Asma Deeb, Ashraf M. El-Ghul5, Khalid Bel’eed Akkari, Ashref A. Tawil, Abdul Shlebak. The Year in Ramadan Fasting Research (2017): A Narrative Review of the literature. Ibnosina J Med Biomed Sci 2018;10:2-39.

2. Shlebak AA. Platelet genesis: Unraveling an incredible journey! Ibnosina J Med Biomed Sci 2017;9:4-101.

3. Shlebak AA, Bain BJ. Training Future Haematologists, a privilege or a burden? “A trainer’s view”. BJH 2017. DOI: 10.1111/bjh.14697  .

4. Shlebak A A, Alexia D Katsarou, George Adams, Fiona Fernando. A novel mutation in exon 2 of FGB caused by c.221G>T[pic] substitution, predicting the replacement of of the native Arginine at position 74 with a Leucine (p.Arg74Leu[pic]) in a Kurdish family with dysfibrinogenaemia and familial venous and arterial thrombosis. Thromb and Thrombolysis Journal Thromb Thrombolysis (2016);1-8. DOI:10.1007/s11239-016-1439-z.

5. Shlebak AA, Polly Sandhu, Vernisha Ali, Garth Jones, Christopher Baker. The impact of the DoH Commissioning for Quality and Innovation incentive on the venous thromboembolism risk assessment implementation in hospitalised patients: A single institution experience over a 4-year cycle, a quality improvement outcome. JRSM Open 2016. 6; 7(6): 2054270416632702.

6. Shlebak AA. Cerebral venous thrombosis as a manifestation of antiphospholipid syndrome. J Clin Path; 2016; 69 (4):337-43.

7. Pintilie H, Raghunanan S, Shlebak A, Everitt A, Foster C. Venous sinus thrombosis in a patient with perinatally acquired HIV, a paediatric case report HIV MEDICINE 2016 17:36-36.

8. Shlebak AA, Anthony Poles, Richard Manning, Shaikha Almuhareb, Josu De La Funte, Mike Mitchell and Geoff Lucas. A novel homozygous c.800C>G substitution in GP1BA exon2 predicting the replacement 1 of the native Serine at codon 267 with a premature termination codon (p.Ser267*) in a Kuwaiti family with Bernard-Soulier syndrome. 2015 Acta Haematology 2015;134:193-198 (DOI: 10.1159/000381328

9. Victoria Campbell, 1 Kevin Marriott, 1 Rex Stanbridge, 2 and Shlebak AA. Successful Aortic Aneurysm Repair in a Woman with Severe von Willebrand (Type 3) Disease. Case Rep Hematol. Case Rep Hematol 2015 19;2015:703803.

10. Shlebak AA. Novel Oral Anticoagulants: A New Era in Anti-Thrombotic Therapy. Ibnosina J Med BS 2013:247-253.

11. Samantha Coulson, Aruchuna Mohanaruban, Abdul Shlebak and Antoni Sergot. (2012). An unusual cause of bleeding in an elderly patient. Clinical Medicine 2012, Vol 12, No 2: 150–2.

12. Neave EL, Schwarb H, Shlebak A, Layton DM, Apperley JF, Pavlu J. (2012) Lymphodepletion chemotherapy followed by donor leukocytes for post transplantation relapse of myelofibrosis after previous donor leukocyte infusion failure. Eur J Haematol 2012.

13. Brooks C; Burbridge J; Marks S; Shlebak A; Ryley S. A novel rearrangement in an atypical myeloproliferative neoplasm with subsequent development of an unrelated clone following transformation to AML. British Human Genetics Conference 2011; 48:S85-S85.

14. Bentley P, Banerjee S, Hamady M, Gordon M, Davis J, Marley S, Williamson D, McColgan P, Mehta A, Waldman A, Quest R, McRobbie D, Shlebak A, Nicholls J, Habib N, Chataway J. Phase I trial of intra-arterial autologous CD34+ haematopoeitic stem cells in acute ischaemic stroke. 2011 Int J Stroke.

15. Hutchinson CV, Burthem J, Bisland M, Carey P, Crotty G, Devalia V, Janda B, Gordon W, Harrison CN, Murray J, Shlebak A, Thomas A, Wilkins B, McMullin MF. British Society for Haematology, slide session, annual scientific meeting, Glasgow, 2008. Int J Lab Hematol. 2010 Apr;32(2):174-83.Publisher weblink DOI

16. Shlebak AA, Iqbal Malik. (2009) Managing heparin in patients with prosthetic cardiac valves “balancing the risk”. Heart 2009; 95:1643-1645

17. Purkayastha Sanjay; Shlebak Abdul. Haematological Considerations: thrombosis in surgery. In Hospital Surgery, foundations in surgical practice, 41-47.. Cambridge Uni Press, USA (01 Apr 2009).

18. Purkayastha Sanjay; Shlebak Abdul. Haematological Considerations: Bleeding. In Hospital Surgery, Foundations in Surgical Practice, 48-56. Eds: Omer Aziz, Sanjay Purkayastha and Paraskevas Paraskeva. Cambridge Uni Press, USA (2009).

19. Purkayastha Sanjay; Shlebak Abdul. Haematological Considerations: Blood Products and Transfusion. In Hospital Surgery: Foundations in Surgical Practice. 1, 1:59-63. Eds: Omer Aziz, Sanjay Purkayastha, Paraskevas Paraskeva. Cambridge Uni Press, USA (2009).

20. Purkayastha Sanjay; Uprichard James; Shlebak Abdul. Haematological Considerations: Haemorrhage (massive-bleeding protocol). In Hospital Surgery: Foundations in Surgical Practice. 1, 1:57-58. Eds: Omer Aziz, Sanjay Purkayastha, Paraskevas Paraskeva. Cambridge Uni Press, USA (2009).

21. Shlebak AA. Pathophysiological Aspects of Coagulation. In HAEMOSTASIS IN SURGERY. 1, 1:1-92. Eds: Nadey S Hakim & Ruben Canelo. Imperial College Press, UK (2007).

22. Rashid ST; Thursz MR; Razvi NA; Voller R; Orchard T; Shlebak AA. (Nov 2005). Venous thromboprophylaxis in UK medical inpatients. J R Soc Med. 98:507-512. Publisher weblink DOI.

23. Bose P; Black S; Kadyrov M; Bartz C; Shlebak A; Regan L; Huppertz B. (Dec 2004). Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol. 191:2125-2131. Publisher weblink DOI.

24. Milne M; Stevenson K J; Craig S; Shlebak A; Amponsah E; McCarthy P; Allaw A. (2003). Improving the quality of INR determination in the anticoagulantion clinic. Journal of thrombosis and Haemostasis. 1.

25. Rai R; Backos M; Elgaddal S; Shlebak AA; Regan L. (Feb 2002). Factor V Leiden and recurrent miscarriage-prospective outcome of untreated pregnancies. Hum Reprod. 17:442-445. Publisher weblink

26. Shlebak AA, Lennox A, Smout J, Thompson K, Wolfe J. Anticoagulant induced skin necrosis: Association with Heparin-induced Thrombocytopenia and Protein S Deficiency. 2002; Br J Haematol

27. Randle E, Bakos M, Rae R, Marriot K, Lopez L, Regan L, Shlebak AA. The prevalence of antibody isotopes against phosphlipids and b-2-glycoproteins in women with recurrent miscarriage. 2002; Brit J Haem, 117 (suppl. 1) 49-93

28. Rai R; Shlebak AA; Cohen H; Backos M; Holmes Z; Marriott K; Regan L. (May 2001). Factor V Leiden and acquired activated protein C resistance among 1000 women with recurrent miscarriage. Hum Reprod. 16:961-965. Publisher weblink.

29. AF Lennox, J Smout, A Shlebak, JHN Wolfe. Warfarin-induced Skin Necrosis: Association with Heparin-induced Thrombocytopenia and Protein S Deficiency. EJVES Extra, 2001 – Elsevier

30. Gallagher D; Shlebak AA. (2001). Outpatient treatment of DVT: time for a change?. Thrombus. 5.

31. Shlebak AA. Haematology and Trasfusionin for MRCS, Royal College of Surgeons Training Manual.

32. Shlebak AA; Marley SB; Roberts IA; Davidson RJ; Goldman JM; Gordon MY. (Jan 1999). Optimal timing for processing and cryopreservation of umbilical cord haematopoietic stem cells for clinical transplantation. Bone Marrow Transplant. 23:131-136. Publisher weblink DOI.

33. Shlebak AA; Roberts IA; Stevens TA; Syzdlo RM; Goldman JM; Gordon MY. (Dec 1998). The impact of antenatal and perinatal variables on cord blood haemopoietic stem/progenitor cell yield available for transplantation. Br J Haematol. 103:1167-1171. Publisher weblink.

34. Shlebak AA; Lewis JL; Marley SB; Davidson RJ; Roberts IAG; Goldman JM; Gordon MY. (15 Nov 1998). The influence of the cytokine receptor signalling class on cord blood progenitor; cell self replication kinetics. Blood. 92:580A-581A.

35. Shlebak AA; Marley SB; Roberts IAG; Goldman JM; Gordon MY. (May 1998). Variables affecting umbilical cord blood progenitor stem cell yield for clinical transplantation. Br J Haematol. 101:96-96.

36. Shlebak AA; Smith DB. (1997). Incidence of objectively diagnosed thromboembolic disease in cancer patients undergoing cytotoxic chemotherapy and/or hormonal therapy. Cancer Chemother Pharmacol. 39:462-466. Publisher weblink.

37. Shlebak AA; Clark PI; Green JA. (1995). Hypersensitivity and cross-reactivity to cisplatin and analogues. Cancer Chemother Pharmacol. 35:349-351. Publisher weblink.

38. Clark RE; Shlebak AA; Creagh MD. (Dec 1994). Delayed commencement of granulocyte colony-stimulating factor following autologous bone marrow transplantation accelerates neutrophil recovery and is cost-effective. Leuk Lymphoma. 16:141-146. Publisher weblink.

Poster presentation

1. Shlebak A. A. Variables affecting umbilical cord blood progenitor/stem cell yield for clinical transplantation. Annual Scientific Meeting of the British Society for Haematology (Glasgow), 1998.

2. Shlebak A. A. Maternal and fetal factors that may influence umbilical cord blood progenitor/stem cell yield for clinical use. 3rd Eurocord Transplant Concerted Action Workshop (France), 1998.

3. Shlebak A. A., Lewis J. L., Marley S. B., Davidson R. J., Roberts I. A. G., Goldman J. M., Gordon M. Y. The influence of the cytokine signalling class on the kinetics of cord blood progenitor self-replication. American Society of Haematology, 40th Annual meeting (Miami Beach, Florida), 1998.

4. Shlebak A. A., Lennox A, Smout J, Thopson K & Wolfe J. Anticoagulation induced skin necrosis, BSH, 2002.

5. Randle E., Bakos M, Rae R, Marriot K, Lopez LR, Regan L, Shlebak A. A. The prevalence od antibody isotypes against phospholipids and b-2 GP in women with recurrent misccarige. BSH 2002.

6. Milne M; Stevenson K J; Craig S; Shlebak A; Amponsah E; McCarthy P; Allaw A. (2003). Improving the quality of INR determination in the anticoagulantion clinic. Journal of thrombosis and Haemostasis. 2003.

Oral Presentations

1. Shlebak A, A. Haematology referral pathways & update on recent developments in anticoagulation. Central London CCGs. 10th January 2019.

2. Shlebak A, A. New therapeutic developments in cancer associated thrombosis. The national association of UK anaesthetist, London. 13th December 2018.

3. Shlebak A, A. London Baratric & renal disease group. Perioperative anticoagulation. 31st October 2018 (invited speaker).

4. Shlebak A, A. Cancer associated thrombosis: Mastercalss Royal Marsden Hospital, London. 9th October 2018.

5. Shlebak A, A. Emergency Day Junior Haematology Trainees-Pan London. Coagulation Emergencies. London Deanery. 19th September 2018.

6. Shlebak A, A. Thrombosis and Cancer. Imperial College, London. Haemostasis Short Course for Consultants and Advanced Trainees, Sep 2018.

7. Shlebak A, A. Antiphospholipid Antibody Syndrome. Imperial College, London. Haemostasis Short Course for Consultants and Advanced Trainees, Sep 2018.

8. Shlebak A, A. Haematology referral pathways for local CCGs, Hammersmith & Fulham.. 19th July 2018.

9. Shlebak A, A. Out of hospital anticoagulation. Central London CCGs training day. Jan 2018.

10. Shlebak A, A. Out of hospital anticoagulation. Westmister CCGs training day. July 2017.

11. Shlebak A, A. Anticoagulants today "spoilt for choice"  (Guest lecture). London Cardiovacsular Society. June 2016

12. Shlebak A, A. Optimising Community Anticoagulation  (Guest lecture). Brent CCG. April 2016.

13. Shlebak A, A. Thrombophilia & VTE: an update. Royal Guards Hospital, KSA, Riyadh, 2016.

14. Shlebak A, A. Haematology Training in the UK. Royal Guards Hospital, KSA, Riyadh, 2016.

15. Shlebak A, A. Cancer Associated Thrombosis  (Guest lecture). Saudi Society Bone Marrow Transplantation. Riyadh, KSA. Feb 2016.

16. Shlebak A, A. Novel Anticoagulants today  (Guest lecture). Saudi Society Bone Marrow Transplantation. Riyadh, KSA. Feb 2016.

17. Shlebak A, A. Anticoagulation "old and New"  (Guest lecture). (Guest lecture). London Cardiovacsular Society. June 2016

18. Shlebak A, A. NOACs in stroke preventon in AF for Nurses, Pizer, July 2015

19. Shlebak A, A. The usefulness (or lack of it) of thrombophilia testing in women? April 2015.

20. Shlebak A, A. Thrombosis and Cancer. Imperial College, London. Haemostasis Short Course for Consultants and Advanced Trainees, Sep 2015.

21. Shlebak A, A. Are thrombophilia tests any use?. Imperial College, London. Haemostasis Short Course for Consultants and Advanced Trainees, Sep 2015.

22. Shlebak A, A. St Mary’s Grand Rounds: An unusual cause of bleeding? March 2015.

23. Shlebak A, A. Thrombosis and Cancer. Imperial College, London. Feb 2015.

24. Haemostasis Short Course for Consultants and Advanced Trainees, Feb 2015.

25. Shlebak A, A. Are thrombophilia tests any use?. Imperial College, London. Haemostasis Short Course for Consultants and Advanced Trainees, Feb 2015.

26. Shlebak A, A. Managing patients on warfarin: reversal of bleeding and

bridging. GP education. October 2014

27. Shlebak A, A. Thrombosis and Cancer. Imperial College, London. Haemostasis Short Course for Consultants and Advanced Trainees, Sep 2014.

28. Shlebak A, A. Are thrombophilia tests any use?. Imperial College, London. Haemostasis Short Course for Consultants and Advanced Trainees, Sep 2014.

29. Shlebak A, A. Heparin induced thrombocytopenia. Imperial College, London. Haemostasis Short Course for Consultants and Advanced Trainees, Feb 2014.

30. Shlebak A, A. Are thrombophilia tests any use?. Imperial College, London. Haemostasis Short Course for Consultants and Advanced Trainees, Feb 2014.

31. Shlebak A, A. St Mary’s Grand Rounds: VTE & cancer. How effectice is prophylaxis? Nov 2013

32. Shlebak A, A. St Mary’s Grand Rounds. CQUIN. Can we do it? Feb 2013.

33. Shlebak A, A. Royal Society of Medicine, Sweat and Blood Series: Haematological Emergencies. June 2012.

34. Brooks C; Burbridge J; Marks S; Shlebak A; Ryley S. A novel rearrangement in an atypical myeloproliferative neoplasm with subsequent development of an unrelated clone following transformation to AML. British Human Genetics Conference. Sep 2011

35. Shlebak A, A; Geoff Lucas. St Mary’s Grand Rounds: GP trafficking. Acquired platelkt disorder. Feb 2011.

36. Shlebak A, A. The Obstetrics Grand Round, Marshall University, WV, USA. Thrombophilia and Pregnancy “Evidence-based perspective” 2010.

37. Shlebak A, A. The 4th Cancer Conference, Sabratha, Libya. Prognostic Indicators in Acute Leukaemia. Sabratha 2009.

38. Shlebak A, A. The 3rd Cancer Conference, Sabratha, Libya. Monoclonal antibodies in NHL. Sabratha 2007.

39. Shlebak A, A. The 3rd Cancer Conference, Sabratha, Libya. VTE and Cancer. Sabratha 2007.

40. Shlebak A, A. The 3rd Cancer Conference, Sabratha, Libya. The role of MDT in Haematological services. Sabratha 2007.

41. Shlebak A, A. St Mary’s Grand Rounds: A female with Haemophilia. Feb 2005.

42. Shlebak A, A. Arab Medical University Symposium. Benghazi, Libya. Management of NHL. Benghaz. 2005.

43. Shlebak A, A. 1st Libyan doctors conference, Tripoli, Libya. Haemophilia. Tripoli. 2005.

44. Shlebak A, A. 1st Libyan doctors conference, Tripoli, Libya. Role of Primary care. European Model of Medical Care. Tripoli. 2005.

45. Shlebak A, A. UK HIT School. Warfarin induced skin necrosis. Belfrey. UK, 2003.

46. R Johnston. Shlebak AA. Warfarin induced skin necrosis. 32nd Annual Course Advances in Haematology. Imperial College, Hammersmith Hospital, London, 2000.

47. Shlebak A, A. Variables affecting umbilical cord blood progenitor/stem cell yield for clinical transplantation. Annual Stem cell Meeting. Birmingham, 1998.

48. Shlebak A, A. G6PD. Advances in Haematology. RPMS, Hammersmith Hospital, London, 1997

Our paper was shortlisted for the following award

[pic]

Top of Form

January 28, 2016

The Best Papers From our 2015 Young Investigators

[pic]DiscussThe STEM CELLS Translational Medicine Young Investigator Award honors a young scientist who is principal author of a significant research paper published in STEM CELLS Translational Medicine. The 3rd annual award went to Dustin R. Wakeman, Ph.D. Here, we feature Dr. Wakeman’s papers as chosen by a panel of judges composed of our Senior Editors. Below are the finalists for the 2015 award. The STEM CELLS Translational Medicine Editors support the efforts of these emerging researchers and encourage the development of these young investigators who are making significant impacts in this field, thus fostering the future of their clinical applications. 

Find out more about the winner of the 2015 STEM CELLS Translational Medicine Young Investigator Award.

Human Neural Stem Cells Survive Long Term in the Midbrain of Dopamine-Depleted Monkeys After GDNF Overexpression and Project Neurites Toward an Appropriate Target

Dustin R. Wakeman, D. Eugene Redmond, Jr., Hemraj B. Dodiya, John R. Sladek, Jr., Csaba Leranth, Yang D. Teng, R. Jude Samulski, Evan Y. Snyder

Stem Cells Trans Med 2014; 3:692-701; doi:10.5966/sctm.2013-0208

A Multiplex High-Throughput Gene Expression Assay to Simultaneously Detect Disease and Functional Markers in Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium

Marc Ferrer, Barbara Corneo, Janine Davis, Qin Wan, Kiyoharu Joshua Miyagishima, Rebecca King, Arvydas Maminishkis, Juan Marugan, Ruchi Sharma, Michael Shure, Sally Temple, Sheldon Miller, Kapil Bharti

Stem Cells Trans Med 2014; 3:911-922; doi:10.5966/sctm.2013-0192

Intra-Arterial Immunoselected CD34+ Stem Cells for Acute Ischemic Stroke

Soma Banerjee, Paul Bentley, Mohammad Hamady, Stephen Marley, John Davis, Abdul Shlebak, Joanna Nicholls, Deborah A. Williamson, Steen L. Jensen, Myrtle Gordon, Nagy Habib, Jeremy Chataway

Stem Cells Trans Med 2014; 3:1322-1330; doi:10.5966/sctm.2013-0178

Induced Pluripotent Stem Cells Reveal Functional Differences Between Drugs Currently Investigated in Patients With Hutchinson-Gilford Progeria Syndrome

Sophie Blondel, Anne-Laure Jaskowiak, Anne-Laure Egesipe, Amelie Le Corf, Claire Navarro, Véronique Cordette, Cécile Martinat, Yacine Laabi, Karima Djabali, Annachiara de Sandre-Giovannoli, Nicolas Levy, Marc Peschanski, Xavier Nissan

Stem Cells Trans Med 2014; 3:510-519; doi:10.5966/sctm.2013-0168

Optimized Cell Survival and Seeding Efficiency for Craniofacial Tissue Engineering Using Clinical Stem Cell Therapy

Archana Rajan, Emily Eubanks, Sean Edwards, Sharon Aronovich, Suncica Travan, Ivan Rudek, Feng Wang, Alejandro Lanis, Darnell Kaigler

Stem Cells Trans Med 2014; 3:1495-1503; doi:10.5966/sctm.2014-0039

Human Finger-Prick Induced Pluripotent Stem Cells Facilitate the Development of Stem Cell Banking

Hong-Kee Tan,Cheng-Xu Delon Toh, Dongrui Ma, Binxia Yang, Tong M ing Liu, Jun Lu, Chee-Wai Wong, Tze-Kai Tan, Hu Li, Christopher Syn, Eng-Lee Tan, Bing Lim, Yoon-Pin Lim, Stuart A. Cook, Yuin-Han Loh

Stem Cells Trans Med 2014;3:586-598; doi:10.5966/sctm.2013-0195

Our paper was covered on the BBC news including live interview of myself on BBC news:

|[pic] |BBC NEWS CHANNEL |News services |

| | |Your news when you want it |

| | | |

| | | |

|News Front Page |[|Last Updated: Tuesday, 1 November 2005, 02:22 GMT [pic] |

|World |p|[pic] |

|UK |i|E-mail this to a friend |

|England |c|Printable version |

|Northern Ireland |]| |

|Scotland | | |

|Wales | | |

|Business | | |

|Politics | |Patients 'miss out' on clot care |

|Health | | |

|Medical notes | |[pic] |

|Education | |Some hospital patients are at higher risk of clots |

|Science & Environment | | |

|Technology | |Two-thirds of NHS patients at risk of blood clots do not get preventative treatments, a study suggests. |

|Entertainment | |Researchers looked at 1,062 patients at two English teaching hospitals and found only a third of eligible patients got any treatment - despite |

|Also in the news | |guidelines. |

|----------------- | |They warn in the Journal of the Royal Society of Medicine that there must be greater awareness of the risks and preventative treatments made available. |

|Video and Audio | |DVT contributes to around 10% of deaths among hospital patients each year. |

|----------------- | |[pic] |

|Have Your Say | |[pic]The information is out there |

|Magazine | |Dr David Keeling, Royal College of Physicians advisor |

|In Pictures | | |

|Country Profiles | |DVTs occur in the leg veins. These clots can break off and lodge in the small vessels in the lung. |

|Special Reports | |If this occurs the condition is called a pulmonary embolism, which is fatal in about a third of cases without treatment. |

|[pic]RELATED BBC SITES | |Preventable deaths |

|SPORT | |DVTs are a common manifestation of venous thromboembolism (VTE). |

|WEATHER | |VTE can be caused by surgery. But it is also the most preventable cause of mortality in medical patients staying in hospital. |

|CBBC NEWSROUND | |Experts in the field advise that, to prevent clots occurring, patients can either be given heparin, a blood-thinning treatment, or surgical stockings. |

|ON THIS DAY | |The researchers looked at medical inpatients in two major English teaching hospitals. |

|EDITORS' BLOG | |They assessed 862 patients of which 89% were found to have moderate and high risk of developing VTE. |

| | |Of these, 71% did not receive any form of prophylaxis. |

| | |Of the 29% who did, expert guidelines about what kind of preventative treatment patients should receive were implemented correctly in only 4% of |

| | |moderate and high-risk patients. |

| | |The researchers then made presentations to doctors from the medical specialties at the hospitals to improve their understanding of the experts' |

| | |recommendations. |

| | |'Action needed' |

| | |Six months later, the researchers went back to the hospitals to see what had changed. |

| | |They evaluated the care of 200 patients, and found the use of preventative, or prophylactic, treatments had increased very slightly, to 31%. However, |

| | |all those patients were now receiving the right treatment. |

| | |The Commons Health Committee raised concerns over clot prevention for NHS patients in March of this year. |

| | |The government then announced its drugs and treatments watchdog, the National Institute for Health and Clinical Excellence, was drawing up official |

| | |guidance on the issue, due out in 2007. |

| | |But lead researcher Dr Abdul Shlebak of St Mary's Hospital, London - one of the hospitals which took part in the study - told the BBC News website that |

| | |was too far away. |

| | |"There is a huge amount of information around about the subject now. 2007 is too long to wait for official guidance." |

| | |"Clinicians and policymakers need to act on these findings if we are to reduce the incidence of VTE and prevent fatalities in hospitals." |

| | |The researchers are calling for measures including a DVT "tick sheet" attached to drug charts to be compiled for all patients on admission and greater |

| | |understanding of DVT in medical and nursing education |

| | |They also want dedicated teams charged with the task of raising awareness and auditing the use of preventative treatments to be established. |

| | |Dr David Keeling, who advised the Commons Health Committee on behalf of the Royal College of Physicians, said: "The expert guidelines were published |

| | |last year, and are very comprehensive. |

| | |"The information is out there." |

| | |He said that, in addition to the NICE guidance, a specialist committee of the British Society of Haematology was also drawing up guidelines, which |

| | |should be available within months. |

| | |A spokesman for the Department of Health said: "We take this issue very seriously. Patients are already getting a good variety of treatments for VTE but|

| | |we recognise that more needs to be done. |

| | |"There is a great deal of knowledge about how to prevent and treat VTE. |

| | |"The challenge is to ensure that the NHS is aware of and implements this good practice." |

| | | |

| | |[pic] |

| | |BBC NEWS:VIDEO AND AUDIO |

| | |A DVT sufferer talks about her symptoms |

| | |[pic] |

| | |[pic] |

| | |[pic] |

| | |SEE ALSO: |

| | |NHS rapped on blood clot deaths |

| | |08 Mar 05 |  Health |

| | |Study reveals 'tiny' flying risk |

| | |03 Nov 03 |  Health |

| | |Pulmonary embolism |

| | |27 Aug 03 |  N-P |

| | |[pic] |

| | |[pic] |

| | |RELATED INTERNET LINKS: |

| | |Royal Society of Medicine |

| | |Department of Health |

| | |British Society of Haematology |

| | |The BBC is not responsible for the content of external internet sites |

| | |[pic] |

| | |TOP HEALTH STORIES |

| | |Hospitals 'eyeing private market' |

| | |Stem cell method put to the test |

| | |Stem cell 'hope' for arthritis |

| | |[pic]| News feeds |

| | |[pic] |

| | | |

Top of Form

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download